Nanollose Ltd
ASX:NC6
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.016
0.085
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| AU |
|
Nanollose Ltd
ASX:NC6
|
21m AUD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
385B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
184.4B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
169B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.3B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.1B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.2B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
47.8B USD |
Loading...
|
Market Distribution
| Min | -14 949 200% |
| 30th Percentile | -526.4% |
| Median | -25.2% |
| 70th Percentile | 6.1% |
| Max | 145 596.9% |
Other Profitability Ratios
Nanollose Ltd
Glance View
Nanollose Ltd. engages in research, development and promotion of nanocellulose technology. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2017-10-18. The firm is focused on advancing technologies relating to the production, processing and applications of microbial cellulose. The firm's products include Nullarbor Fibre, Nullarbor Garment and Jelli Grow. The firm uses fermentation process to grow fibers, as an alternative to plant-derived cellulose fibers. The firm develops and commercializes a tree-free nullarbor lyocell fiber for clothing, and textiles and nufolium for non-woven fiber applications, including personal wipes through Birla Cellulose. The company has developed a process that creates microbial cellulose from industrial organic and agricultural waste, which can be transformed into rayon fibers.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Nanollose Ltd is -11 593.3%, which is below its 3-year median of -5 832.8%.
Over the last 3 years, Nanollose Ltd’s Operating Margin has increased from -23 434.8% to -11 593.3%. During this period, it reached a low of -23 434.8% on May 30, 2022 and a high of -1 462.4% on Dec 31, 2023.